ArticleClinical pharmacology and therapeutics2022

An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2.

Lauren E Walker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.